Methyllycaconitine citrate (Synonyms: MLA) |
| Catalog No.GC13678 |
Methyllycaconitine citrate (MLA), a norditerpenoid alkaloid isolated from the seeds of Delphinium brownie.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 112825-05-5; 351344-10-0
Sample solution is provided at 25 µL, 10mM.
Methyllycaconitine citrate (MLA), a norditerpenoid alkaloid isolated from the seeds of Delphinium brownie. Methyllycaconitine citrate (MLA) is an antagonist of α7-containing neuronal nicotinic acetylcholine receptors (α7nAChR)[2].
Pretreatment with 5 and 10 uM MLA inhibited the decreased cell viability induced by Aβ25-35, which suggested that MLA had a protective effect against Aβ-induced cytotoxicity. Furthermore, cell viability did not decrease after exposure to MLA (2.5, 5, 10, 20 uM), which suggests a good safety profile[1].Because of Methyllycaconitine citrate (MLA) is specific, concentration-dependent, reversible, and voltage-independent antagonism, it could inhibit acetylcholine- and anatoxin-induced whole-cell currents in cultured fetal rat hippocampal neurons[3].
When test the influence of Methyllycaconitine citrate on acute METH effects and neurotoxicity in mice, using both in vivo and in vitro models. MLA inhibited METH-induced climbing behavior by 50%. Acute effects after 30-min preincubation with 1µM METH also included a decrease in striatal synaptosome dopamine (DA) uptake, which was prevented by MLA. METH-induced neurotoxicity was assessed in vivo in terms of loss of striatal dopaminergic terminals (73%) and of tyrosine hydroxylase levels (by 90%) at 72 h post-treatment, which was significantly attenuated by MLA[4]. 50 nM Methyllycaconitine citrate partially inhibited (by 16%) [(3)H]dopamine release from rat striatal synaptosomes stimulated with 10 microM nicotine. Other alpha7-selective antagonists had no effect. Similarly, Methyllycaconitine citrate (50 nM) inhibited [(3)H]dopamine release evoked by the partial agonist (2-chloro-5-pyridyl)-9-azabicyclo[4.2.1]non-2-ene (UB-165) (0.2 microM) by 37%[5]. Methyllycaconitine citrate was administered to animals allowed to self-administer nicotine intravenously, and also to animals that had been prepared with nicotine-containing osmotic mini-pumps and trained on a brain stimulation reward procedure. The results indicated that pretreatment with the highest doses of MLA used (3.9 and 7.8 mg/kg) significantly reduced nicotine self-administration at two doses of self-administered nicotine (0.03 and 0.06 mg/kg/infusion) [6]. Vaccination altered methyllycaconitine toxicity in mice and that vaccination may be useful in decreasing the effects of larkspur toxins in animals[7].
References:
[1]. Zheng X, Xie Z, et,al. Methyllycaconitine alleviates amyloid-β peptides-induced cytotoxicity in SH-SY5Y cells. PLoS One. 2014 Oct 31;9(10):e111536. doi: 10.1371/journal.pone.0111536. PMID: 25360664; PMCID: PMC4216102.
[2]. Kalappa BI, Sun F, et,al. A positive allosteric modulator of α7 nAChRs augments neuroprotective effects of endogenous nicotinic agonists in cerebral ischaemia. Br J Pharmacol. 2013 Aug;169(8):1862-78. doi: 10.1111/bph.12247. PMID: 23713819; PMCID: PMC3753841.
[3]. Alkondon M, Pereira EF, et,al. Blockade of nicotinic currents in hippocampal neurons defines methyllycaconitine as a potent and specific receptor antagonist. Mol Pharmacol. 1992 Apr;41(4):802-8. PMID: 1569927.
[4]. Escubedo E, Chipana C, et,al. Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum: involvement of alpha7 nicotinic receptors. J Pharmacol Exp Ther. 2005 Nov;315(2):658-67. doi: 10.1124/jpet.105.089748. Epub 2005 Aug 2. PMID: 16076935.
[5]. Mogg AJ, Whiteaker P, et,al.Methyllycaconitine is a potent antagonist of alpha-conotoxin-MII-sensitive presynaptic nicotinic acetylcholine receptors in rat striatum. J Pharmacol Exp Ther. 2002 Jul;302(1):197-204. doi: 10.1124/jpet.302.1.197. PMID: 12065717.
[6]. Markou A, Paterson NE. The nicotinic antagonist methyllycaconitine has differential effects on nicotine self-administration and nicotine withdrawal in the rat. Nicotine Tob Res. 2001 Nov;3(4):361-73. doi: 10.1080/14622200110073380. PMID: 11694204.
[7]. Lee ST, Stegelmeier BL,et,al. Evaluation of vaccination against methyllycaconitine toxicity in mice. J Anim Sci. 2003 Jan;81(1):232-8. doi: 10.2527/2003.811232x. PMID: 12597394.
| Cell experiment [1]: | |
Cell lines | The human neuroblastoma cell line SH-SY5Y |
Preparation Method | Cells were cultured in RPMI-1640 supplemented with 10% FBS at 37 °C. Cells at 60-70% confluence were treated with concentrations of Aβ25-35, Methyllycaconitine citrate, rapamycin or Aβ25 35 with or without Methyllycaconitine citrate. |
Reaction Conditions | 2.5-20uM Methyllycaconitine citratefor 24h |
Applications | Pretreatment with 5 and 10 uM Methyllycaconitine citrate inhibited the decreased cell viability induced by Aβ25-35, which suggested that MLA had a protective effect against Aβ-induced cytotoxicity. Furthermore, cell viability did not decrease after exposure to Methyllycaconitine citrate (2.5, 5, 10, 20 uM), which suggests a good safety profile |
| Animal experiment [2]: | |
Animal models | White Swiss-Webster male mice |
Preparation Method | Mice were initially injected with primary injection solution (0.2 mL) for a dose of 50 µg of hapten fetuin conjugate( Methyllycaconitine citrate and MLA-BSA). Booster injections (0.2 mL) with the same dose of hapten fetuin conjugate in incomplete Freund's adjuvant were given at 3-wk intervals. Control mice were initially injected s.c. with control primary injection solution. At the same time, the treated mice received booster injections the control mice were given control booster injections (0.2 mL). |
Dosage form | 1 mg/mL Methyllycaconitine citrate 0.2ML |
Applications | Vaccination altered Methyllycaconitine citrate toxicity in mice and that vaccination may be useful in decreasing the effects of larkspur toxins in animals. |
References: | |
| Cas No. | 112825-05-5; 351344-10-0 | SDF | |
| Synonyms | MLA | ||
| Chemical Name | 20-ethyl-1α,6β,14α,16β-tetramethoxy-4-[[[2-[(3S)-3-methyl-2,5-dioxo-1-pyrrolidinyl]benzoyl]oxy]methyl]-aconitane-7,8-diol, 2-hydroxy-1,2,3-propanetricarboxylate | ||
| Canonical SMILES | CCN1C[C@]2(COC(C3=C(N4C(C[C@H](C)C4=O)=O)C=CC=C3)=O)CC[C@H](OC)[C@]56[C@]2([H])[C@H](OC)[C@]([C@@H]16)(O)[C@](C[C@H](OC)[C@@]([H])(C7)[C@@H]8OC)(O)[C@]8([H])[C@]57[H].OC(CC(O)=O)(C(O)=O)CC(O)=O | ||
| Formula | C37H50N2O10.C6H8O7 | M.Wt | 874.93 |
| Solubility | Soluble in water to 100 mM | Storage | Desiccate at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.1429 mL | 5.7147 mL | 11.4295 mL |
| 5 mM | 0.2286 mL | 1.1429 mL | 2.2859 mL |
| 10 mM | 0.1143 mL | 0.5715 mL | 1.1429 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 17 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *